New therapies requiring ultra large scale monoclonal Ab production in microalgae

单克隆抗体以精确的特异性靶向病原体和分子，并且对于治疗和诊断是必需的。它们目前是使用高科技/有限容量的哺乳动物细胞培养物制造的，这限制了它们的低剂量应用。我们的目标是通过在光合作用驱动的绿色藻类系统中快速、低成本、大规模生产有价值的药用抗体来实现新的高剂量抗体疗法（例如抗病毒治疗、被动免疫）。

Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.